Intellia’s Phase 3 win puts the first in-vivo CRISPR therapy on a regulatory path

A scribe in a medieval scriptorium copies a scroll with a glowing quill, while a tapestry behind shows a key unlocking a chain binding a figure.

Lonvoguran-ziclumeran met every endpoint in the HAELO trial, the first Phase 3 test of in-vivo gene editing, but the data leave open questions about durability and cost.

A single intravenous infusion of lonvoguran-ziclumeran eliminated attacks and the need for ongoing medication in most hereditary angioedema patients for the six-month evaluation period of the Phase 3 HAELO trial.

A busy harbor at sunset with galleons changing sails from white to black, merchants arguing on the dock, and one ship sailing away with black sails.

Trial design and results

The HAELO study was a randomized, double-blind, placebo-controlled trial. Intellia reported that enrollment finished within nine months of the first patient being dosed in January 2025, with nearly half the participants enrolled in the United States. A single 50 mg dose inactivated the KLKB1 gene in liver cells, lowering kallikrein and bradykinin levels. The company stated that the primary endpoint and all key secondary endpoints were met and that the safety profile was favorable. Rolling submission of a biologics license application to the FDA began in 2026; the company projects a possible U.S. launch in the first half of 2027 if approved.

A stone bridge under construction over a deep river gorge, with workers hoisting stones, three completed arches on the far side, and a blueprint on a rock.

In-vivo versus ex-vivo delivery

Prior approved CRISPR therapies required removing a patient’s cells, editing them in a laboratory, and returning them. Lonvoguran-ziclumeran uses lipid nanoparticles to deliver the CRISPR components directly into hepatocytes via a standard intravenous infusion. This approach avoids per-patient cell manufacturing and specialized apheresis equipment. The six-month efficacy window used in HAELO matches the duration regulators requested for measuring attack reduction.

Competitive implications

The result supplies the first large-scale evidence that in-vivo CRISPR editing can reach its target organ and produce a measurable clinical effect. Companies whose pipelines remain centered on ex-vivo editing now confront a concrete alternative. Whether CRISPR Therapeutics, Editas Medicine, or Beam Therapeutics accelerate their own in-vivo programs, form partnerships, or maintain current strategies will be visible in pipeline updates and capital-allocation disclosures over the next two years.

Next candidates

Intellia’s NTLA-2001 program for transthyretin amyloidosis already holds RMAT designation. Other liver-targeted monogenic indications under consideration for in-vivo editing include hemophilia B and phenylketonuria. The regulatory experience gained from the lonvoguran-ziclumeran rolling BLA may shorten timelines for subsequent programs if the FDA continues to accept similar endpoints and submission formats.

Cost and access considerations

Hereditary angioedema patients currently rely on daily or on-demand therapies whose cumulative cost can reach six figures annually. A one-time infusion that removes both attack risk and chronic medication would shift the cost structure to an upfront payment, potentially offset by outcomes-based arrangements. Intellia has not disclosed pricing.

The HAELO trial demonstrates that in-vivo CRISPR editing can be executed at Phase 3 scale. Whether the approach expands to additional indications will depend on longer-term durability data and payer negotiations that have not yet occurred.